A detailed history of Hantz Financial Services, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 109 shares of EXEL stock, worth $4,634. This represents 0.0% of its overall portfolio holdings.

Number of Shares
109
Holding current value
$4,634
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025

BUY
$32.38 - $39.16 $3,529 - $4,268
109 New
109 $4,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $13.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Hantz Financial Services, Inc. Portfolio

Follow Hantz Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hantz Financial Services, Inc. with notifications on news.